From “undruggable” to controllable: Milestones in pancreatic cancer therapy
-
-
REFERENCES
[1] Mannucci A. and Goel A. (2026). Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. CA Cancer J. Clin. 76:e70035. DOI:10.3322/caac.70035 [2] Rojas L.A., Sethna Z., Soares K.C., et al. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144−150. DOI:10.1038/s41586-023-06063-y [3] Cregg J., Edwards A.V., Chang S., et al. (2025). Discovery of Daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. J. Med. Chem. 68:6064−6083. DOI:10.1021/acs.jmedchem.4c02314 [4] Wolpin B.M., Park W., Garrido-Laguna I., et al. (2026). Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N. Engl. J. Med. 394:1790−1802. DOI:10.1056/NEJMoa2505783 [5] Srivastava R. and Rana T.R.K. (2026). Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine. Front. Med. (Lausanne) 13:1727976. DOI:10.3389/fmed.2026.1727976 -
ABOUT THIS ARTICLE
Cite this article:
Qi H., Zhang S. and Liu M. (2027). From “undruggable” to controllable: Milestones in pancreatic cancer therapy. The Innovation Medicine 5:100273. https://doi.org/10.59717/j.xinn-med.2027.100273
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Qi H., Zhang S. and Liu M. (2027). From “undruggable” to controllable: Milestones in pancreatic cancer therapy. The Innovation Medicine 5:100273. https://doi.org/10.59717/j.xinn-med.2027.100273
Format
Content
DownLoad:
-
Figure 1.
From “undruggable” to controllable PDAC: mRNA vaccination and pan-RAS targeting
